ArticleJournal of natural medicines2025
Processing reduces diester diterpenoid alkaloids content of fuzi products, resulting in reduced toxicity and modified bioactivities.
Article in Journal of natural medicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toxicology and detoxification processing of Fuzi (Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Fuzi is a generic term for various processed products of the lateral roots of Aconitum carmichaelii Debeaux, with a long history of medicinal use including hypoglycemic, anti-inflammatory, and immunity-enhancing. However, the toxicity of Fuzi limits its widespread use. Different processing methods have been used to minimize toxicity and improve the medicinal properties of Fuzi. Three processed Fuzi products were prepared according to Chinese Pharmacopoeia and their chemical compositions were qualitatively and quantitatively analysed using UPLC-MS. The toxicity, antioxidant properties and bioactivity changes were assessed in Caenorhabditis elegans. A total of 99 compounds were preliminarily identified, and a subsequent multivariate analysis showed significant differences among the different processed products in terms of chemical compositions. The processing led to a significant loss of alkaloids, decrease in the contents of total polyphenols and flavonoids, and a decrease in antioxidant capacity while increasing the total polysaccharide and uronic acid contents in Yan Fuzi and Hei Shunpian as well as the content of monoester diterpenoid alkaloids in Hei Shunpian and Bai Fupian. Furthermore, the processed products prevented cold stress in C. elegans. In conclusion, processing altered the composition and reduced the toxicity of Fuzi and led to differences in the pharmacological activities of different processed Fuzi products. These results provide a theoretical basis for the in-depth pharmacological study and application of processed products of Fuzi.
Indexed as
Identifiers
40195203What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.